This clinical practice guideline is a focused update on management of Clostridioides difficile
infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for …

Clostridium difficile (C. difficile) is a Gram-positive, spore-forming, anaerobic bacillus, which
is widely distributed in the intestinal tract of humans and animals and in the environment. In …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Bile acids (BAs) mediate the crosstalk between human and microbial cells and influence
diseases including Clostridioides difficile infection (CDI). While bile salt hydrolases (BSHs) …

Importance The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains
of Clostridia on prevention ofClostridioides difficileinfection (CDI) is unknown. Objective To …

Importance A safe and effective treatment for recurrentClostridioides difficileinfection (CDI) is
urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted …

Triptolide (TP), a traditional Chinese medicine, has been reported to be effective in the
treatment of autoimmune diseases and exerting antineoplastic activity in several human …

Background Clostridium difficile is the most common cause of infectious diarrhea in
hospitalized patients. Recurrences are common after antibiotic therapy. Actoxumab and …

Infection of the colon with the Gram-positive bacterium Clostridium difficile is potentially life
threatening, especially in elderly people and in patients who have dysbiosis of the gut …